June 30, 2025
Trial Data Indicates Cell Therapy May Reverse GA Damage
Surgical delivery of OpRegen RPE cell therapy produced sustained anatomical and functional improvements in geographic atrophy, according to 36-month data.
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/pj0b5iux/1025-omd-cover-image.png
Ophthalmology Management
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/43vf3gam/cover_oct25_web.jpg
Retinal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/0s0ksauu/0925-gp-cover.jpg
Glaucoma Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/0jsmmz3o/op_1025_cover_final.jpg
Ophthalmic Professional
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/jdnlmuh3/1025-oasc-cover-final.jpg
The Ophthalmic ASC
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/aqbjxwjw/pp-cover.jpg
Presbyopia Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/npjdtl1w/cp_november_cover.jpg
Corneal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/mvqdq2hc/nrp_cover_october_2024.jpg
New Retinal Physician
June 30, 2025
Surgical delivery of OpRegen RPE cell therapy produced sustained anatomical and functional improvements in geographic atrophy, according to 36-month data.
By Jim Gallagher, senior managing editor
June 24, 2025
PER-001 is being developed for long-term control of diabetic retinopathy by addressing underlying ischemia.